Scancell Holdings Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Phil L'Huillier

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Phil L'Huillier

no data

Permanencia

Dr. Phil L'Huillier is CEO & Director of Scancell Holdings plc from November 18, 2024. Prior to joining Scancell, Dr L'Huillier served as CEO and Managing Director of CatalYm GmbH, a pioneering cancer immu...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lindy Durrant	Chief Scientific Officer & Director and Founder	no data	UK£388.17k	0.22% € 348.6k
Sathijeevan Nirmalananthan	CFO, Company Secretary & Director	1.3yrs	UK£43.18k	sin datos
Phil L'Huillier	CEO & Director	no data	sin datos	sin datos
Samantha Paston	Head of Translational Research	5.8yrs	sin datos	sin datos
Adrian Parry	Head of Manufacturing	5.8yrs	sin datos	sin datos
Mandeep Sehmi	Head of Business Development	1.2yrs	sin datos	sin datos
Callum Scotthasbeen	Head of Development	less than a year	sin datos	sin datos
Alex Hayward	Head of Finance	less than a year	sin datos	sin datos
Nermeen Varawalla	Chief Medical Officer	less than a year	sin datos	sin datos

1.0yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SCP no se considera experimentado ( 1 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lindy Durrant	Chief Scientific Officer & Director and Founder	16.6yrs	UK£388.17k	0.22% € 348.6k
Sathijeevan Nirmalananthan	CFO, Company Secretary & Director	less than a year	UK£43.18k	sin datos
Phil L'Huillier	CEO & Director	no data	sin datos	sin datos
Florian Nicolas Reinaud	Non-Executive Director	less than a year	sin datos	sin datos
Ursula Ney	Independent Non-Executive Director	5.1yrs	UK£40.00k	sin datos
Jean-Michel Yves Cossery	Non-Executive Chairman	1.8yrs	UK£100.00k	0.049% € 76.6k
Martin Diggle	Non-Executive Director	5.4yrs	sin datos	sin datos
Susan Clement-Davies	Independent Non-Executive Deputy Chair	4.2yrs	UK£55.00k	sin datos

3.0yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de SCP no se considera experimentada (3 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Scancell Holdings Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Scancell Holdings plc Announces CEO Changes

Scancell Holdings plc, Annual General Meeting, Oct 25, 2024

Scancell Holdings plc Appoints Florian Reinaud to the Board

Scancell Holdings plc Appoints Sath Nirmalananthan to the Board

Scancell Holdings plc Directorate and Executive Changes Changes

Scancell Holdings plc, Annual General Meeting, Nov 29, 2023

Recent updates

Scancell Holdings plc Announces Further Positive Data from the Ongoing SCOPE Trial of SCIB1 with Double CPIs for Advanced Melanoma

Scancell Holdings plc Announces CEO Changes

Scancell Holdings plc, Annual General Meeting, Oct 25, 2024

Scancell Holdings plc to Report Fiscal Year 2024 Results on Sep 24, 2024

New minor risk - Financial data availability

Scancell Holdings plc Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial

Scancell Holdings plc Announces That A Group of Medical Oncologists in the Field of Melanoma Treatment Reviewed and Strengthened Scancell's Plan for A Phase 2/3 Registration Study Following Completion of the Ongoing Scope Study

Scancell Holdings plc Appoints Florian Reinaud to the Board

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Market cap size

Scancell Holdings plc Appoints Sath Nirmalananthan to the Board

Scancell Holdings plc Directorate and Executive Changes Changes

Scancell Holdings plc to Report First Half, 2024 Results on Jan 30, 2024

Scancell Holdings plc Announces Update on SCOPE Trial

Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £11.897217 million.

Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £12.672161 million.

Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £8.08 million.

Scancell Holdings plc, Annual General Meeting, Nov 29, 2023

Scancell Holdings plc to Report Q4, 2023 Results on Oct 12, 2023

Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free

Scancell Holdings plc Announces Positive Data from the First Stage in its Phase 2 Scope Trial with SCIB1 Cancer Vaccine Delivered by Needle Free Injection for Advanced Melanoma

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets SCIB1/iSCIB-1+ and Modi-1

Scancell Holdings plc Announces Appointment of Dr Mandeep Sehmi as Head of Business Development

Scancell Appoints Sath Nirmalananthan as CFO

New minor risk - Financial data availability

New minor risk - Market cap size

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1

Scancell Holdings plc Announces Positive Response in Covidity Trial

Scancell Holdings plc Announces Executive Changes

Scancell Holdings plc to Report First Half, 2023 Results on Jan 25, 2023

Less than half of directors are independent

Scancell Holdings plc Announces First Patient Dosed in Expansion Phase of Modify

Scancell Holdings plc, Annual General Meeting, Nov 21, 2022

Scancell Holdings plc Announces Board Changes

Scancell Holdings plc Announces First Patient Dosed in Cohort 2 of the ModiFY Phase 1 Clinical Trial

Scancell Holdings plc to Produce TCB Antibodies

Scancell Holdings plc Announces an Update to the Phase 2 Scope Clinical Trial

Scancell Holdings plc Announces the Enrolment and Treatment of the First Patient in Its Multicentre Modi-1 Clinical Trial (Modify) At Imperial College London, Hammersmith Hospital

Less than half of directors are independent

Scancell Holdings plc Announces Modi-1 Phase 1/2 Trial Open for Recruitment

Scancell Holdings plc Announces Update on Covidity Clinical Trial

Scancell Holdings plc Announcedsfurther Progress of the Phase 1 Covidity Clinical Trial Being Conducted At the University of Cape Town (UCT) Lung Institute in South Africa

Scancell Holdings plc Announces the UK's Medicines and Healthcare Products Regulatory Authority Approves the Clinical Trial Application to Initiate the First-in-Human Phase I/II Clinical Study of Modi-1

CEO & Director Clifford Holloway has left the company

Scancell Holdings plc Announces COVIDITY Phase 1 Clinical Trial Planned in South Africa and UK for Novel Bivalent COVID-19 Vaccine

New 90-day high: €0.35

Scancell Holdings plc Announces an Update on its SCIB2 Clinical Development Partnership with Cancer Research UK

Scancell Holdings plc Appoints Gillies O'Bryan-Tear as Chief Medical Officer and Robert Miller as Medical Director

Scancell Holdings plc to Report Fiscal Year 2020 Results on Oct 16, 2020

Cobra Biologics and Scancell Holdings plc Announces Collaboration to Manufacture COVID-19 Vaccine

Scancell Holdings plc announced that it expects to receive £1.3 million in funding from Cherwell Capital plc, Oxford Technology Management Limited, Oxford Capital Partners LLP, Seneca Partners Limited, Octopus Investments Limited

Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £9.007417 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad